Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes

What Was Tested

Researchers studied Insulin Lispro in this randomized controlled trial publication.

NPH-human insulin was used for basal substitution in both groups.

A questionnaire comprised of four primary domains was used to measure some quality of life aspects of the patients.

Who Took Part

According to the abstract, 107 patients were involved.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

In a randomized, open-label, controlled cross-over trial, 107 patients with type 1 diabetes were treated with either regular human insulin or insulin lispro, a rapid-acting insulin analogue.

How the Study Was Run

The design is described as randomized, open-label and crossover.

The patients were allocated by chance, so the Insulin Lispro group and the comparison group should start out alike.

Being open-label, the Insulin Lispro study did not mask who received what.

In the crossover set-up each of the patients took both Insulin Lispro and the comparison in turn, acting as their own control.

What Was Measured

A questionnaire comprised of four primary domains was used to measure some quality of life aspects of the patients.

The subject headings attached to it are Amino Acid Sequence, Blood Glucose, Diabetes Mellitus, Type 1, Eating, Glycated Hemoglobin, Hyperglycemia and Hypoglycemic Agents.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Insulin Lispro in 107 patients.

The publication is from 1996 (Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association), a journal based in Germany.

More context: the Insulin Lispro compound page, all human trials.